<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409315</url>
  </required_header>
  <id_info>
    <org_study_id>CTDM/FQ1</org_study_id>
    <nct_id>NCT03409315</nct_id>
  </id_info>
  <brief_title>Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients</brief_title>
  <acronym>PERFECT</acronym>
  <official_title>Prospective Evaluation of impRoving Fluoroquinolone Exposure Using Centralized Tdm in TB Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, multi-centre, prospective study to investigate the feasibility of centralized
      TDM of moxifloxacin and levofloxacin in MDR-TB patients by determining turn-around time
      between sampling and receiving dosing advice.

      In addition, the effect of TDM will be evaluated by comparing treatment results of
      prospective patients receiving TDM with historical controls without TDM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of centralized TDM</measure>
    <time_frame>1 week</time_frame>
    <description>Turn-around time between plasma sampling and receiving dosing advice</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of centralized TDM</measure>
    <time_frame>2 months</time_frame>
    <description>Comparison of % patients with converted sputum smear and culture between prospective patients with TDM and matched historical controls without TDM (1:2)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin, prospective</arm_group_label>
    <description>Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of moxifloxacin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin, prospective</arm_group_label>
    <description>Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of levofloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin, historical controls</arm_group_label>
    <description>Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of moxifloxacin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin, historical controls</arm_group_label>
    <description>Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of levofloxacin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Centralized Therapeutic Drug Monitoring</intervention_name>
    <description>Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.</description>
    <arm_group_label>Moxifloxacin, prospective</arm_group_label>
    <arm_group_label>Levofloxacin, prospective</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Sputum smear and culture positive MDR-TB patients treated with either moxifloxacin or
        levofloxacin in multiple clinical centres worldwide.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pulmonary MDR-TB

          -  Sputum smear and sputum culture positive at baseline

          -  Oral administration of either moxifloxacin or levofloxacin

          -  Written informed consent (for use of the medical data)

        Exclusion Criteria:

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-WIllem Alffenaar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan-WIllem Alffenaar, PhD</last_name>
    <phone>+31503614071</phone>
    <email>j.w.c.alffenaar@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone van den Elsen, BSc</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Prince Charles and Caboolture Hospitals</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Burke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre of Pulmonology and Tuberculosis</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alena Skrahina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ©lio Fraga Reference Center</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margareth Dalcolmo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athens Chest Hospital &quot;Sotiria&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charalampos Moschos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alma Mater Studiorum University of Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marina Tadolini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reuh Tldc</name>
      <address>
        <city>Upeslejas</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liga Kuksa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcela Munoz Torrico</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen Beatrixoord</name>
      <address>
        <city>Haren</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Onno Akkerman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vila Nova Gaia/Espinho Medical School</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raquel Duarte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cape Town, Lung Insitute</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keertan Dheda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith Bruchfeld</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kibong'oto Infectious Diseases Hospital</name>
      <address>
        <city>Sanya Juu</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Heysell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Tiberi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belarus</country>
    <country>Brazil</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Tanzania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Jan-Willem C Alffenaar</investigator_full_name>
    <investigator_title>PhD, PharmD</investigator_title>
  </responsible_party>
  <keyword>Centralized Therapeutic Drug Monitoring</keyword>
  <keyword>Fluoroquinolones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

